Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery

Semin Cancer Biol. 2022 May:80:195-204. doi: 10.1016/j.semcancer.2020.05.006. Epub 2020 May 16.

Abstract

Cancer cells exhibit molecular characteristics that confer them different proliferative capacities and survival advantages to adapt to stress conditions, such as deregulation of cellular bioenergetics, genomic instability, ability to promote angiogenesis, invasion, cell dormancy, immune evasion, and cell death resistance. In addition to these hallmarks of cancer, the current cytostatic drugs target the proliferation of malignant cells, being ineffective in metastatic disease. These aspects highlight the need to identify promising therapeutic targets for new generations of anti-cancer drugs. Toxins isolated from snake venoms are a natural source of useful molecular scaffolds to obtain agents with a selective effect on cancer cells. In this article, we discuss the recent advances in the molecular mechanisms of nine classes of snake toxins that suppress the hallmarks of cancer by induction of oxidative phosphorylation dysfunction, reactive oxygen species-dependent DNA damage, blockage of extracellular matrix-integrin signaling, disruption of cytoskeleton network and inhibition of growth factor-dependent signaling. The possible therapeutic implications of toxin-based anti-cancer drug development are also highlighted.

Keywords: Cell death; Chemosensitization; Metastasis; Migrastatics; Toxins.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Carcinogenesis
  • Cell Transformation, Neoplastic
  • Drug Discovery
  • Humans
  • Neoplasms* / drug therapy
  • Snake Venoms / pharmacology

Substances

  • Antineoplastic Agents
  • Snake Venoms